349 related articles for article (PubMed ID: 32508203)
1. Pharmacokinetics of nucleoside/nucleotide reverse transcriptase inhibitors for the treatment and prevention of HIV infection.
Wonganan P; Limpanasithikul W; Jianmongkol S; Kerr SJ; Ruxrungtham K
Expert Opin Drug Metab Toxicol; 2020 Jul; 16(7):551-564. PubMed ID: 32508203
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
Spaulding A; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
[TBL] [Abstract][Full Text] [Related]
3. Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence.
Orkin C; Llibre JM; Gallien S; Antinori A; Behrens G; Carr A
HIV Med; 2018 Jan; 19(1):18-32. PubMed ID: 28737291
[TBL] [Abstract][Full Text] [Related]
4. Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.
Trang TP; Dong BJ; Kojima N; Klausner JD
Expert Opin Drug Saf; 2016 Sep; 15(9):1287-94. PubMed ID: 27391203
[TBL] [Abstract][Full Text] [Related]
5. Comparative safety review of recommended, first-line single-tablet regimens in patients with HIV.
Ciccullo A; Baldin G; Putaggio C; Di Giambenedetto S; Borghetti A
Expert Opin Drug Saf; 2021 Nov; 20(11):1317-1332. PubMed ID: 34018892
[No Abstract] [Full Text] [Related]
6. The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection.
Özdener AE; Park TE; Kalabalik J; Gupta R
Expert Rev Anti Infect Ther; 2017 May; 15(5):467-481. PubMed ID: 28322067
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.
Moss JA; Srinivasan P; Smith TJ; Butkyavichene I; Lopez G; Brooks AA; Martin A; Dinh CT; Smith JM; Baum MM
Antimicrob Agents Chemother; 2014 Sep; 58(9):5125-35. PubMed ID: 24936594
[TBL] [Abstract][Full Text] [Related]
8. New nucleoside/nucleotide backbone options: a review of recent studies.
Ruane PJ; DeJesus E
J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S21-9. PubMed ID: 15319666
[TBL] [Abstract][Full Text] [Related]
9. Nucleoside and nucleotide reverse transcriptase inhibitors in children.
Giaquinto C; Rampon O; Penazzato M; Fregonese F; De Rossi A; D'Elia R
Clin Drug Investig; 2007; 27(8):509-31. PubMed ID: 17638393
[TBL] [Abstract][Full Text] [Related]
10. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
[TBL] [Abstract][Full Text] [Related]
11. Evaluating emtricitabine + rilpivirine + tenofovir alafenamide in combination for the treatment of HIV-infection.
Mu Y; Pham M; Podany AT; Cory TJ
Expert Opin Pharmacother; 2020 Mar; 21(4):389-397. PubMed ID: 31957507
[No Abstract] [Full Text] [Related]
12. Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients.
Ogbuagu O
Expert Rev Anti Infect Ther; 2016 Dec; 14(12):1113-1126. PubMed ID: 27797606
[TBL] [Abstract][Full Text] [Related]
13. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
Acosta RK; Willkom M; Andreatta K; Liu H; Martin R; Parvangada A; Martin H; Collins S; White KL
J Acquir Immune Defic Syndr; 2020 Nov; 85(3):363-371. PubMed ID: 32701823
[TBL] [Abstract][Full Text] [Related]
14. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
Pruvost A; Negredo E; Théodoro F; Puig J; Levi M; Ayen R; Grassi J; Clotet B
Antimicrob Agents Chemother; 2009 May; 53(5):1937-43. PubMed ID: 19273671
[TBL] [Abstract][Full Text] [Related]
15. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 48-week efficacies of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimens: a systematic review and network meta-analysis.
Gallien S; Massetti M; Flandre P; Leleu H; Descamps D; Lazaro E
HIV Med; 2018 Jul; ():. PubMed ID: 30004176
[TBL] [Abstract][Full Text] [Related]
17. HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
Harris M; Ganase B; Watson B; Harrigan PR; Montaner JSG; Hull MW
AIDS Res Ther; 2017 Nov; 14(1):59. PubMed ID: 29096670
[TBL] [Abstract][Full Text] [Related]
18. Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142.
Huang JS; Hughes MD; Riddler SA; Haubrich RH;
HIV Clin Trials; 2013; 14(5):224-34. PubMed ID: 24144899
[TBL] [Abstract][Full Text] [Related]
19. Emerging reverse transcriptase inhibitors for HIV-1 infection.
Rai MA; Pannek S; Fichtenbaum CJ
Expert Opin Emerg Drugs; 2018 Jun; 23(2):149-157. PubMed ID: 29737220
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral agents in pre-exposure prophylaxis: emerging and advanced trends in HIV prevention.
Yap PK; Loo Xin GL; Tan YY; Chellian J; Gupta G; Liew YK; Collet T; Dua K; Chellappan DK
J Pharm Pharmacol; 2019 Sep; 71(9):1339-1352. PubMed ID: 31144296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
